下载本文档
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEForskolinCat. No.: HY-15371CAS No.: 66575-29-9Synonyms: Coleonol; Colforsin分式: CHO分量: 410.5作靶点: Adenylate Cyclase; Autophagy作通路: GPCR/G Protein; Autophagy储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数
2、据体外实验 DMSO : 100 mg/mL (243.61 mM; Need ultrasonic)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.09 mM); Clear solution2. 请依序添加每种溶剂: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (6.09 mM); Clear solution1/3 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 Forskolin
3、种有效的 腺苷酸环化酶 激活剂,结合到 I 型腺苷酸环化酶 IC50 为 41 nM,激活 I 型腺苷酸环化酶 EC50 为 0.5 M。IC50 & Target IC50: 41 nM (Adenylyl cyclase) 1EC50: 0.5 M (Adenylyl cyclase) 1体外研究 Forskolin (Fsk) is a naturally occurring diterpene isolated from Coleus forskholii, directly activates adenylylcyclase (AC) through its catalytic su
4、bunit to increase intracellular levels of cyclic adenosine monophosphate(cAMP) 1. Forskolin (Fsk) affects the proliferation of the human T-cell lines such as Kit 225 and MT-2.Forskolin treatment inhibits the proliferation of both Kit 225 and MT-2 cells in a dose-dependent manner withan IC50 equal to
5、 5 M Fsk. Forskolin treatment (10-100 M) increases cAMPi levels 5- to 20-fold abovebasal levels, which reache maximum levels between 50-100 M Forskolin 2.体内研究 The Forskolin (Fsk)-treated Mrp4-/- mice shows an increased number of Ki67-positive and cleaved caspase3-positive ECs, a significant decrease
6、 in the amount of pericyte coverage, and a reduced number of emptysleeves. In pups exposed to hyperoxia (75% oxygen) from P7 to P12, the Mrp4-/- mice shows a significantincrease in the unvascularized retinal area 3. The average blood glucose in the healthy rat group is102.121.94 mg/dL, 101.253.56 fo
7、r control group and 1032.08 in forskolin group. The data shows thatglucose levels at the end of the study are lower in forskolin group, with a significant difference according tothe statistical tests applied (p=0.03) 4.PROTOCOLCell Assay 2 Quiescent Kit 225 or MT-2 cells are seeded into 96-well plat
8、es at 5104 cells per well. Cells are thenpretreated for 1 h with 1% DMSO (vehicle) or Forskolin at 1, 5, 10, 25, 50, and 100 Mconcentrations. Thecells are stimulated with IL-2 and cultured for an additional 20 h at 37C. Control cells are treated with 1%DMSO for 20 h. During the final 4 h of incubati
9、on, the cells are pulsed with 3Hthymidine at a concentrationof 0.5 Ci/200 L. Cells are harvested onto fiberglass filters and analyzed using liquid scintillation counting2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 3Administration 34 C57
10、BL/6J mice are used. Mrp4-knockout mice, which are established and repeatedly backcrossed to theC57BL/6J mice. Forskolin is injected intraperitoneally into neonatal mice at postnatal days 4 (P4) and 5 (P5).Mice injected with DMSO serve as the controls. The treated mice are euthanized at P6, and thei
11、r retinas areisolated for whole-mount immunohistochemistry (IHC). The effect of different concentrations of Forskolin onthe survival rate and retinal vasculature is first tested, and the optimal concentration is determined, 1.0 g/50L (0.3 mg/kg) at P4 and 1.5 g/50 L (0.5 mg/kg) at P5, used to compar
12、e the retinal vascular phenotypesbetween WT mice and Mrp4-deficient mice.Rats 42/3 Master of Small Molecules 您边的抑制剂师www.MedChemEMale Wistar rats, aged 10-14 weeks old, with a mean weight of 300 g50 g, are divided into four groups; 19are experimentally induced to develop diabetes, and 8 are maintaine
13、d in a healthy condition. Both diabeticand healthy rats receive no Forskolin (control), or 6 mg/kg per day of Forskolin, administered orally for 8weeks. Blood glucose levels are determined in each group before and after Forskolin treatment. The diabeticrats are tested two weeks after confirming the
14、presence of diabetes (three weeks after the induction) andafter eight weeks of the designated treatment.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 Biomaterials. 2018 Dec 6;193:30-46. Br J Pharmacol. 2019 Aug;176(16):2962-2976. Int J Bio
15、l Macromol. 2018 Oct 1;117:42-50. J Lipid Res. 2018 Feb;59(2):330-338. ACS Chem Neurosci. 2018 Dec 19;9(12):3175-3185.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Robbins JD, et al. Forskolin carbamates: binding and activation studies with type I adenylyl cyclase. J Med Chem
16、. 1996 Jul5;39(14):2745-52.2. Rodriguez G, et al. Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptorcomplex. J Biol Chem. 2013 Mar 8;288(10):7137-46.3. Matsumiya W, et al. Forskolin modifies retinal vascular development in Mrp4-knockout mice. Invest Ophthalmol Vis Sci. 2012 Dec7;53(13):8029-35.4. Ros-Silva M, et al. Effect of chronic administration of forskolin on glycemia and oxidative stress in rats with and without experimenta
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2025年度食堂承包经营单位劳动合同书3篇
- 2024年医疗卫生服务改进合同
- 2025年度集装箱自助餐厅租赁合同2篇
- 2025年新房电商团购合作执行标准合同模板3篇
- 2024年路砖项目可行性研究报告
- 2024年超临界流体萃取装置项目可行性研究报告
- 2025至2031年中国控制旋钮行业投资前景及策略咨询研究报告
- 2025年度蔬菜配送网络建设与运营合同范本3篇
- 2025-2030年(全新版)中国蓝莓果汁行业市场运营现状及投资前景规划研究报告
- 2025-2030年中国静力水准行业运行状况与前景趋势分析报告
- 二年级下册加减混合竖式练习360题附答案
- GB/T 21709.5-2008针灸技术操作规范第5部分:拔罐
- 大三上-诊断学复习重点
- 应收账款的管理培训课件
- 2021年道路交通安全法期末考试试题含答案
- 股东变更情况报告表
- 自带药物治疗告知书
- 房产中介门店6S管理规范
- 吞咽解剖和生理研究
- TSG11-2020 锅炉安全技术规程
- 异地就医备案个人承诺书
评论
0/150
提交评论